N/A
N=421
Rheumatoid Arthritis Satisfaction Outcome Research
Rheumatoid Arthritis
Bottom Line
View on ClinicalTrials.gov: NCT03703817 ↗Enrolled (actual)
421
Serious AEs
0.0%
Results posted
Mar 2021
Primary outcome: Primary: Treatment Satisfaction Questionnaire for Medication (TSQM) Version 1.4 — 62.271; 64.191; 93.390; 96.603 units on a scale — p=0.3648
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Adult, Older Adult · 19+ yrs
- Sex
- All
- Sponsor
- Pfizer
- Primary completion
- Mar 2020
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Treatment Satisfaction Questionnaire for Medication (TSQM) Version 1.4 |
62.271; 64.191; 93.390; 96.603; 68.785; 64.946 | 0.3648 |
| SECONDARY European Quality of Life-5 Dimensions-3 Level (EQ-5D-3L) Index Score |
0.812; 0.808 | 0.1602 |
| SECONDARY European Quality of Life-Visual Analogue Scale (EQ-VAS) Score |
65.403; 65.668 | 0.9921 |
Summary
RA satisfaction OR: This study aim to compare treatment satisfaction and quality of life between patients who have been using tofacitinib citrate and patients who have been using adalimumab for 6 months or more and less than 2 year in RA treatment of rheumatoid arthritis.
Eligibility Criteria
Inclusion Criteria
- Patients aged 19 years or older
- Patients diagnosed with RA
- Treatment groups:
- Tofacitinib citrate users: Patients currently on treatment with tofacitinib citrate in RA therapy for 6 months or more 2) Adalimumab users: Patients currently on treatment with adalimumab in the RA therapy for 6 months or more 4. Reading and writing with enough proficiency to complete assessment instruments in Korean
Exclusion Criteria
- Patients currently on tofacitinib citrate or adalimumab for 2 year or more
- Patients taking Azathioprine and cyclosporine
- Patients participating in other drug interventional study
- Patients who have been treated with bDMARDs except Rheumatoid arthritis.
Data sourced from ClinicalTrials.gov (NCT03703817). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.